We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
H.C. Wainwright initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $58 price target The firm views the company’s lead asset mitapivat as a “pipeline within a drug” and ...
Agios Pharmaceuticals has filed for regulatory approval of its drug Mitapivat (PYRUKYND) to treat adult patients with both non-transfusion-dependent and transfusion-dependent forms of alpha- or ...
CAMBRIDGE, MA – Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a biopharmaceutical company focused on cellular metabolism to treat cancer and rare genetic diseases, announced the upcoming departure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback